Additional Information

Description

Ruxience 100 mg SDV (Single-Dose Vial), available by prescription only, is a medication used in the treatment of various autoimmune disorders and certain types of cancer. This injectable formulation contains rituximab, a monoclonal antibody that targets CD20-positive B-cells, a type of immune cell involved in autoimmune responses and certain cancers like non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Administered intravenously, Ruxience works by binding to CD20 receptors on B-cells, which triggers their destruction through antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity. This mechanism helps reduce the number of abnormal B-cells responsible for disease progression, thereby managing symptoms and potentially inducing remission.

Each single-dose vial contains 100 mg of rituximab and is sterilely packaged to ensure safety and efficacy. Healthcare providers determine the appropriate dosage and infusion schedule based on the patient's specific condition, medical history, and response to treatment. Regular monitoring is essential to assess treatment effectiveness, manage potential side effects such as infusion reactions or immune suppression, and adjust therapy as needed.